全球中枢神经系统（CNS）生物标记市场规模、份额、趋势和成长分析报告（2026-2034年）

预计中枢神经系统 (CNS) 生物标记市场将从 2025 年的 71.4 亿美元成长到 2034 年的 150.1 亿美元，2026 年至 2034 年的复合年增长率为 8.61%。

随着神经系统和精神疾病研究的活性化，中枢神经系统生物标记市场持续扩张。生物标记能够提供疾病进展、治疗效果和早期诊断的可测量指标，例如阿兹海默症、帕金森氏症、癫痫和多发性硬化症等疾病。中枢神经系统疾病盛行率的上升、药物研发投入的增加以及对个人化医疗的需求，正在推动临床实践、製药业和研究机构对生物标记的应用。

技术创新正在推动市场成长。先进的成像技术、分子、遗传和蛋白质体学技术能够精准地辨识和监测生物标记。人工智慧驱动的分析、高通量筛检以及与实验室晶片平台的整合，正在提升预测性诊断、临床试验效率和患者分层水准。多重生物标记检测可以同时评估多个通路，有助于改善治疗决策和药物研发成果。

预计未来成长将主要由研发投入增加、人口老化以及精准医疗倡议的扩展所驱动。北美和欧洲凭藉其成熟的临床研究基础设施主导市场，而亚太地区则在不断扩张的製药和神经科学研究中心的推动下，正经历快速的市场应用。学术机构、生物技术公司和製药公司之间的合作正在加速生物标记的发现和检验。中枢神经系统（CNS）生物标记有望成为神经系统疾病治疗的重要工具，从而实现早期疗育、个人化治疗并改善患者预后。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球中枢神经系统（CNS）生物标记市场：依生物标记类型划分

• 市场分析、洞察与预测
• 安全生物标记
• 疗效生物标记
• 验证生物标记
• 其他生物标誌物

第五章 全球中枢神经系统（CNS）生物标记市场：依应用划分

• 市场分析、洞察与预测
• 疾病诊断
• 药物发现与开发
• 个人化医疗
• 其他用途

第六章 全球中枢神经系统（CNS）生物标记市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 诊断检查室
• 学术研究机构
• 其他最终用户

第七章 全球中枢神经系统（CNS）生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • BioMerieux
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche Ltd
  • G-Biosciences
  • Illumina Inc
  • Merck KGaA
  • Myriad Genetics Inc
  • Novartis AG
  • PerkinElmer Inc
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc

The Central Nervous System (CNS) Biomarkers Market size is expected to reach USD 15.01 Billion in 2034 from USD 7.14 Billion (2025) growing at a CAGR of 8.61% during 2026-2034.

The CNS biomarkers market is expanding as neurological and psychiatric disorder research intensifies. Biomarkers provide measurable indicators of disease progression, therapeutic response, and early diagnosis in conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. Rising prevalence of CNS disorders, investment in drug development, and demand for personalized therapies are driving adoption across clinical, pharmaceutical, and research settings.

Technological innovation is fueling market growth. Advanced imaging, molecular, genetic, and proteomic techniques enable precise biomarker identification and monitoring. Integration with AI-driven analytics, high-throughput screening, and lab-on-a-chip platforms enhances predictive diagnostics, clinical trial efficiency, and patient stratification. Multiplex biomarker panels allow simultaneous assessment of multiple pathways, improving therapeutic decision-making and drug development outcomes.

Future growth is expected from increasing R&D investment, aging populations, and expansion of precision medicine initiatives. North America and Europe dominate due to mature clinical research infrastructure, while Asia-Pacific is witnessing rapid adoption fueled by expanding pharmaceutical and neuroscience research hubs. Collaborations between academic institutions, biotech firms, and pharmaceutical companies are accelerating biomarker discovery and validation. CNS biomarkers are poised to become integral tools in neurotherapeutics, enabling early intervention, personalized treatment, and improved patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Biomarker Type

• Safety Biomarker
• Efficacy Biomarker
• Validation Biomarker
• Other Biomarkers

By Application

• Disease Diagnosis
• Drug Discovery And Development
• Personalized Medicines
• Other Applications

By End-Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End-Users

COMPANIES PROFILED

• bioMerieux, BioRad Laboratories Inc, F HoffmannLa Roche Ltd, GBiosciences, Illumina Inc, Merck KGaA, Myriad Genetics Inc, Novartis AG, PerkinElmer Inc, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomarker Type
• 4.2. Safety Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Efficacy Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Validation Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Disease Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Discovery And Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Personalized Medicines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Biomarker Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Biomarker Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Biomarker Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Biomarker Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Biomarker Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 BioMerieux
  • 9.2.2 Bio-Rad Laboratories Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 G-Biosciences
  • 9.2.5 Illumina Inc
  • 9.2.6 Merck KGaA
  • 9.2.7 Myriad Genetics Inc
  • 9.2.8 Novartis AG
  • 9.2.9 PerkinElmer Inc
  • 9.2.10 Siemens Healthineers AG
  • 9.2.11 Sysmex Corporation
  • 9.2.12 Thermo Fisher Scientific Inc